file sharing talktmaTalkTMA Documents

Sharing documents is a great way to exchange and elevate best practices. Feel free to add your documents, algorithms and hand-outs for others to use. You will need to be logged in to download files. Some files are restricted to members of the aHUS National Working Group.

Return to documents home

Please ensure you are logged in order to access or upload files.

Folder Educational Tools

pdf Canadian Apheresis Group (CAG) TTP Management Algorithm


For acquired TTP treatment is recommended as follows:

1. For patients with probable TTP it is recommended that treatment withplasma exchange (PE) be initiated as soon as possible. PE of 1.5 PV should be carried out until remission however, if responseslows or if there is no change, increase daily PE until response. NOTE: the choice of the plasma replacement fluid should be at thediscretion of the treating physician and should be chosen from CSP, SDP, Frozen Plasma or other suitable fluid, without restriction and asrequired by the patient.

2. Steroids may be added to the protocol at disease onset or if no/orslowing response, generally at a dose of 1 mg/kg prednisone orally.If severe end-organ dysfunction is present (e.g. stroke, seizures,myocardial infarction) consider pulsed IV methylprednisolone daily forthree days then reduce to 1 mg/kg prednisone or equivalent.

3. Rituximab should be considered in refractory TTP (no response after5 PE or return of disease in 0 to 30 days post remission).

4. If disease continues to progress, consider rescue therapy with T cellsuppression (cyclophosphamide, cyclosporine), plasma cell suppression(bortezomib) or, if disease continues, a

combination (+/- splenectomy).

5. Rituximab should also be used in patients who achieved remission butwho have subsequently relapsed (i.e. return of disease at least 30 daysafter the last PE).

Canadian Apheresis Group (CAG) TMA Algorithm

About Us

Thrombotic microangiopathy (TMA) is a group of rare disorders affecting the microvasculture of most organ beds. The impact of these diseases on those affected by them is immense. Our understanding of these disorders is rapidly expanding and therapeutic options are beginning to appear. However, many challenges remain when managing TMA and one is a practical one: the diseases are rare and the experts in them are few and spread worldwide. Read more...